Proliposomal intravesical paclitaxel

Drug Profile

Proliposomal intravesical paclitaxel

Alternative Names: TBC-1002; TSD-001

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TesoRx
  • Developer LIPAC Oncology
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer

Most Recent Events

  • 10 May 2017 Chemical structure information added
  • 10 Mar 2017 LIPAC Oncology plans a phase I/II trial for Bladder cancer in USA (NCT03081858)
  • 09 Mar 2017 LIPAC Oncology files an IND application with the USFDA for Bladder cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top